AUG. 1 1 2003

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/FTA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page of

	Complete if Know	
Application Number	09/891,138	FILE
Filing Date	June 25, 2001	TVED
First Named Inventor	Lin, Danley Chi-Hong, etc. 2	1.9 20
Art Unit	1647 FUH CENTER	2003
Examiner Name	Christopher J. Nichols E/	1600
Attorney Docket Number	018781-006210US	1000/2900

U.S. PATENT DOCUMENTS							
		Occurrent Number					
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
C3N	CA	US- 2002/017887 A1	09/26/2002	Hedrick et al.	Vigores Appear		
		US-					
		US-					
		US-	· · · · · · · · · · · · · · · · · · ·				
		US-					
		US-					
		US-					
		US-					
		US-		1			
		US-					
		US-					

			FO	REIGN PA	TENT DOCUM	ENTS		
Examiner Initials*	Cite No. ¹	For		Code* (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
C 322	СВ	PCT	WO 01/79449	A2	10/25/2001	Hyseq, Inc.		0
	CC	PCT	WO 01/90304	A2	11/29/2001	Human Genome Sciences, Inc.		0
	CD	PCT	WO 01/98351	A2	12/27/2001	Incyte Genomics, Inc.		-
	CE	PCT	WO 02/61087	A2	08/08/2002	Lifespan Biosciences, Inc.		-0-
دى	CF	PCT	WO 03/000893	A2	01/03/2003	Decode Genetics EHF.		
								H
		1						ı

Examiner Signature	(- Uir	Date Considered 2 1 2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. The reign Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

OCT 0 1 2002



1

PTO/SB/08B (10-01)

TECH CENTED 1 CARGOSTION use through 10/31/2002. OMB 0651-0031

TECH CENTED 1 CARGOSTION use through 10/31/2002. OMB 0651-0031

TECH CENTED 1 CARGOSTION use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 14498/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shoot	1	of 1	

Complete if Known					
Application Number	09/891,138				
Filing Date	June 25, 2001				
First Named Inventor	Lin, Daniel Chi-Hong, et. al.				
Art Unit	1646 1647				
Examiner Name	Net yet assigned NICHOLS				
Attorney Docket Number	018781-006210US				

				FOREIGN PA	TENT DOCUME	ENTS		
		For	eign Patent Doc	ument		Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Cite Initials* No.1		Country Code ³ Number ⁴ Kind Code ⁴ (# knd		Kind Code ^b (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	۳⁰
600	ВА	EP	1 096 009	A1	05/02/2001	Pfizer Limited et al.		 []
	ВВ	wo	00/22131	A2	04/20/2000	Dominic P. Behan et al.		
1	BC	wo	00/31258	A2	06/02/2000	Ruoping Chen et al.		
	BD	wo	01/25432	A2	04/12/2001	Schering Corporation		
	BE	wo	01/33221	A1	05/10/2001	SmithKline Beecham Corporation et al		0
4/	BF	wo	01/46414	A1	06/28/2001	Banyu Pharmaceutical CO., LTD.		
دلم	BG	wo	01/85793	A2	11/15/2001	Pharmacia & Upjohn Company		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
CSV	вн	STADEL J. et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 18, no. 11, pp. 430-437, (November 1, 1997)						

Examiner Signature	Allias	Date Considered 4/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1388300 v1



Please type a plus sign (+) inside this box

OCT 0 9 2001

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 995, no persons are required respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

TRADApplication Number 09/891,138 June 25, 2001 Filing Date

First Named Inventor Lin, Daniel Chi-Hong 1040 1647 Group Art Unit

(use as many sheets as necessary)

Attorney Docket Number

NICHOL 018781-006 AUSC

Complete if Known

	U.S. PATENT DOCUMENTS								
		U.\$. Pa	atent Docu	ıment		-	Pages, Collegns, Lines.		
Examiner Initials *	Cite No.1	Number	Kind C		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Sages a Relevant Digures Appear		
حبوي	AA	5,871		Α	Conley, et al.	02-16-1999	- 8		
3	AB	5,955	309	Α	Ellis, et al.	09-21-1999			
6	AC	6,063	582_	Α	Conley, et al.	05-16-2000			
حوي	AD	6,204	017	B1	Behan, et al.	03-20-2001			
50	AE	6,222	029	B1	Edwards, et al.	04-24-2001			

Examiner Name

				FOREIC	N PATENT DOCUME	NTS		
Examiner Initials*	Cite No. ¹	Fore Office ³		Ment Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	r⁰
ကွာ	AF	EPO	WO 96/05302	A1	Takeda Chemical Industries, LTD.	02-22-1996		
	AG	EPO	WO 97/24929	A1	Human Genome Sciences, Inc.	07-17-1997		
	АН	EPO	99/06552	A2	Genset	02-11-1999	-	
	Al	EPO	WO 00/11166	A1	Millennium Pharmaceuticals, Inc.	03-02-2000		
	AJ	EPO	WO 00/22131	A2	Behan, et al.	04-20-2000		
	AK	EPO	WO 00/28032	A2	Incyte Pharmaceuticals, Inc.	05-18-2000		
	AL	EPO	WO 00/61628	A1	Human Genome Sciences, Inc.	10-19-2000		
	AM	EPO	01/31014	A2	Pharmacia & Upjohn Company	05-03-2001		
	AN	EPO	WO 00/31258	A2	Arena Pharmaceuticals, Inc.	06-02-2000		
4	AO	EPO	WO 01/36473	A2	Pharmacia & Upjohn Company	05-25-2001		
an	AP	EPO	1090925	A1	Pfizer Limited	04-11-2001		

Examiner Signature	6 Wilo	Date Considered	4/8/2003	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 9 Applicant is to place a check mark here if English language Translation is attached.

							'	
Please	type	a	olus	sign	(+)	inside	this	box

PTO/SB/08A (08-00)

H

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, r

+

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

reduired to registing to a collection of	of information unless it contains a valid	OMB	control nun	nber.			
CARRY	Complete if Known						
THRU THE PROPERTY OF THE PROPE	09/891,138						
Filing Date	June 25, 2001	_					
First Named Inventor	Lin, Daniel Chi-Hong	四			b		
Group Art Unit	4040 (647	五			F		
Examiner Name	NKHOLS	CE	C		۲		
Attorney Docket Number	018781-006210US	Z		y			

FOREIGN PATENT DOCUMENTS									T
	Foreign Patent Document				Date of	Pages, Columns, Lines	<u> </u>	Ī	
Examiner Initials*	Cite No. ¹	Office ³	Number ⁴ C	Kind ode ⁵ (if nown)	nd Applicant of Cited Publicat Pocument Cited Document	Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		•
حوے	AQ	EPO	1096009	A1	Pfizer Limited	05-02-2001			_
	AR	EPO	EP 0892051	A2	Smithkline Beecham Corporation	01-20-1999			•
	AS	EPO	EP 0892051	А3	Smithkline Beecham Corporation	01-20-1999			_
V	AT	JPO	08- 245697		Takeda Chemical Industries, LTD.	09-24-1996			_
8	AU	JPO	11032770	Α	Asahi Kasei Kogyo KK	07-24-1997			-
			<u> </u>					1	

Examiner Signature	CMi la	Date Considered	4	1812003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 SF 1277930 v1